BioCryst Pharmaceuticals Inc (BCRX) stock saw a decline, ending the day at $7.64 which represents a decrease of $-0.09 or -1.16% from the prior close of $7.73. The stock opened at $7.64 and touched a ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year, with ...

Evercore ISI raised the firm’s price target on BioCryst (BCRX) to $12 from $10 and keeps an Outperform rating on the shares.

Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...